Citation: | Chen Quanyu, Jiang Shifang, Xia Renpei, et al. Research progress on immunosuppressants and new drugs for liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 663-670. doi: 10.3969/j.issn.1674-7445.2020.06.003 |
[1] |
STARZL TE, MARCHIORO TL, VONKAULLA KN, et al. Homotransplantation of the liver in humans[J]. Surg Gynecol Obstet, 1963, 117:659-676. http://europepmc.org/articles/PMC2634660;jsessionid=5u9PFSxWXB2NoZDOvXuO.21
|
[2] |
DUTKOWSKI P, LINECKER M, DEOLIVEIRA ML, et al. Challenges to liver transplantation and strategies to improve outcomes[J]. Gastroenterology, 2015, 148(2):307-323. DOI: 10.1053/j.gastro.2014.08.045.
|
[3] |
ZARRINPAR A, BUSUTTIL RW. Liver transplantation: past, present and future[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(7):434-440. DOI:10.1038/nrgastro. 2013.88.
|
[4] |
NANKIVELL BJ, P'NG CH, O'CONNELL PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras[J]. Transplantation, 2016, 100(8):1723-1731. DOI: 10.1097/TP.0000000000001243.
|
[5] |
KOROLCZUK A, CABAN K, AMAROWICZ M, et al. Oxidative stress and liver morphology in experimental cyclosporine A-induced hepatotoxicity[J]. Biomed Res Int, 2016:5823271. DOI: 10.1155/2016/5823271.
|
[6] |
TERANO C, ISHIKURA K, HAMADA R, et al. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: a review of four patients[J]. Nephrology (Carlton), 2018, 23(6):539-545. DOI: 10.1111/nep.13054.
|
[7] |
KINO T, HATANAKA H, HASHIMOTO M, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. I. fermentation, isolation, and physico-chemical and biological characteristics[J]. J Antibiot (Tokyo), 1987, 40(9):1249-1255. DOI: 10.7164/antibiotics.40.1249.
|
[8] |
NEUHAUS P, BLUMHARDT G, BECHSTEIN WO, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. a single center experience[J]. Transplantation, 1995, 59(1):31-40. DOI: 10.1097/00007890-199501150-00007.
|
[9] |
DIEHL R, FERRARA F, MÜLLER C, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches[J]. Cell Mol Immunol, 2017, 14(2):146-179. DOI: 10.1038/cmi.2016.39.
|
[10] |
ORANGE DE, BLACHERE NE, FAK J, et al. Dendritic cells loaded with FK506 kill T cells in an antigen-specific manner and prevent autoimmunity in vivo[J]. Elife, 2013, 2:e00105. DOI: 10.7554/eLife.00105.
|
[11] |
WU AH. Creatine kinase isoforms in ischemic heart disease[J]. Clin Chem, 1989, 35(1):7-13. doi: 10.1093/clinchem/35.1.7
|
[12] |
BOREL JF, FEURER C, GUBLER HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent[J]. Agents Actions, 1976, 6(4):468-475. DOI: 10.1007/BF01973261.
|
[13] |
CALNE RY, ROLLES K, WHITE DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers[J]. Lancet, 1979, 2(8151):1033-1036. DOI: 10.1016/s0140-6736(79)92440-1.
|
[14] |
STARZL TE, KLINTMALM GB, PORTER KA, et al. Liver transplantation with use of cyclosporin A and prednisone[J]. N Engl J Med, 1981, 305(5):266-269. DOI: 10.1056/NEJM198107303050507.
|
[15] |
LOESCHENBERGER B, NIESS L, WÜRZNER R, et al. Calcineurin inhibitor-induced complement system activation via ERK1/2 signalling is inhibited by SOCS-3in human renal tubule cells[J]. Eur J Immunol, 2018, 48(2):330-343. DOI: 10.1002/eji.201747135.
|
[16] |
MORTENSEN LA, BISTRUP C, THIESSON HC. Does mineralocorticoid receptor antagonism prevent calcineurin inhibitor-induced nephrotoxicity?[J]. Front Med (Lausanne), 2017, 4:210. DOI: 10.3389/fmed.2017.00210.
|
[17] |
SANDRINI S, SETTI G, BOSSINI N, et al. Early (fifth day) vs. late (sixth month) steroid withdrawal in renal transplant recipients treated with Neoral(®) plus Rapamune(®): four-yr results of a randomized monocenter study[J]. Clin Transplant, 2010, 24(5):669-677. DOI: 10.1111/j.1399-0012.2009.01171.x.
|
[18] |
LIBERMAN AC, BUDZIÑSKI ML, SOKN C, et al. Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells[J]. Front Endocrinol (Lausanne), 2018, 9:235. DOI: 10.3389/fendo.2018.00235.
|
[19] |
EHRCHEN JM, ROTH J, BARCZYK-KAHLERT K. More than suppression: glucocorticoid action on monocytes and macrophages[J]. Front Immunol, 2019, 10:2028. DOI: 10.3389/fimmu.2019.02028.
|
[20] |
COOPER DKC. Early clinical xenotransplantation experiences-an interview with Thomas E. Starzl, MD, PhD[J]. Xenotransplantation, 2017, 24(2). DOI: 10.1111/xen.12306.
|
[21] |
FUNG JJ. Obituary of Thomas E. Starzl, MD, PhD[J]. Am J Transplant, 2017, 17(5):1153-1155. DOI: 10.1111/ajt.14267.
|
[22] |
HEIDEVELD E, HAMPTON-O'NEIL LA, CROSS SJ, et al. Glucocorticoids induce differentiation of monocytes towards macrophages that share functional and phenotypical aspects with erythroblastic island macrophages[J]. Haematologica, 2018, 103(3):395-405. DOI: 10.3324/haematol.2017.179341.
|
[23] |
VANDEWALLE J, LUYPAERT A, DE BOSSCHER K, et al. Therapeutic mechanisms of glucocorticoids[J]. Trends Endocrinol Metab, 2018, 29(1):42-54. DOI: 10.1016/j.tem.2017.10.010.
|
[24] |
RONCHETTI S, MIGLIORATI G, BRUSCOLI S, et al. Defining the role of glucocorticoids in inflammation[J]. Clin Sci (Lond), 2018, 132(14):1529-1543. DOI: 10.1042/CS20171505.
|
[25] |
MA WT, GAO F, GU K, et al. The role of monocytes and macrophages in autoimmune diseases: a comprehensive review[J]. Front Immunol, 2019, 10:1140. DOI: 10.3389/fimmu.2019.01140.
|
[26] |
KUMAR D, SEHRAWAT S. Divergent effects of a transient corticosteroid therapy on virus-specific quiescent and effector CD8+ T cells[J]. Front Immunol, 2019, 10:1521. DOI: 10.3389/fimmu.2019.01521.
|
[27] |
COUTINHO AE, CHAPMAN KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights[J]. Mol Cell Endocrinol, 2011, 335(1):2-13. DOI: 10.1016/j.mce.2010.04.005.
|
[28] |
FERRARA G, PETRILLO MG, GIANI T, et al. Clinical use and molecular action of corticosteroids in the pediatric age[J]. Int J Mol Sci, 2019, 20(2):444. DOI: 10.3390/ijms20020444.
|
[29] |
ZHANG J, YANG Y, LIU W, et al. Glucocorticoid and mineralocorticoid receptors and corticosteroid homeostasis are potential targets for endocrine-disrupting chemicals[J]. Environ Int, 2019, 133(Pt A):105133. DOI: 10.1016/j.envint.2019.105133.
|
[30] |
RADHAKUTTY A, BURT MG. Management of endocrine disease: critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia[J]. Eur J Endocrinol, 2018, 179(4):R207-R218. DOI: 10.1530/EJE-18-0315.
|
[31] |
HERNÁNDEZ-DÍAZ S, RODRÍGUEZ LA. Steroids and risk of upper gastrointestinal complications[J]. Am J Epidemiol, 2001, 153(11):1089-1093. DOI: 10.1093/aje/153.11.1089.
|
[32] |
WHITTIER X, SAAG KG. Glucocorticoid-induced osteoporosis[J]. Rheum Dis Clin North Am, 2016, 42(1):177-x. DOI: 10.1016/j.rdc.2015.08.005.
|
[33] |
GUPTA S, SHAH P, GREWAL S, et al. Steroid-induced glaucoma and childhood blindness[J]. Br J Ophthalmol, 2015, 99(11):1454-1456. DOI: 10.1136/bjophthalmol-2014-306557.
|
[34] |
CARA CJ, PENA AS, SANS M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice[J]. Med Sci Monit, 2004, 10(11):RA247-RA254. http://www.ncbi.nlm.nih.gov/pubmed/15507865
|
[35] |
GŁADYSZ M, ANDRAŁOJĆ W, CZAPIK T, et al. Thermodynamic and structural contributions of the 6-thioguanosine residue to helical properties of RNA[J]. Sci Rep, 2019, 9(1):4385. DOI: 10.1038/s41598-019-40715-2.
|
[36] |
LEITNER J, DROBITS K, PICKL WF, et al. The effects of cyclosporine A and azathioprine on human T cells activated by different costimulatory signals[J]. Immunol Lett, 2011, 140(1/2):74-80. DOI:10.1016/j.imlet. 2011.06.010.
|
[37] |
COULTHARD SA, BERRY P, MCGARRITY S, et al. Azathioprine with allopurinol: lower deoxythioguanosine in DNA and transcriptome changes indicate mechanistic differences to azathioprine alone[J]. Inflamm Bowel Dis, 2017, 23(6):946-955. DOI:10.1097/MIB. 0000000000001131.
|
[38] |
TSUCHIYA A, AOMORI T, SAKAMOTO M, et al. Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment[J]. Pharmazie, 2017, 72(1):22-28. DOI: 10.1691/ph.2017.6799.
|
[39] |
CUMMINS D, SEKAR M, HALIL O, et al. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation[J]. Transplantation, 1996, 61(11):1661-1662. DOI: 10.1097/00007890-199606150-00023.
|
[40] |
PEYRIN-BIROULET L, CADRANEL JF, NOUSBAUM JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression[J]. Aliment Pharmacol Ther, 2008, 28(8):984-993. DOI: 10.1111/j.1365-2036.2008.03812.x.
|
[41] |
SIEBERT A, PREJS M, CHOLEWINSKI G, et al. New analogues of mycophenolic acid[J]. Mini Rev Med Chem, 2017, 17(9):734-745. DOI: 10.2174/1389557516666161129160001.
|
[42] |
HOSOHATA K, MATSUOKA E, INADA A, et al. Differential profiles of adverse events associated with mycophenolate mofetil between adult and pediatric renal transplant patients[J]. J Int Med Res, 2018, 46(11):4617-4623. DOI: 10.1177/0300060518786917.
|
[43] |
WANG WX, CHENG GG, LI ZH, et al. Curtachalasins, immunosuppressive agents from the endophytic fungus xylaria cf. curta[J]. Org Biomol Chem, 2019, 17(34):7985-7994. DOI: 10.1039/c9ob01552c.
|
[44] |
GO E, TARNAWSKY SP, SHELLEY WC, et al. Mycophenolic acid induces senescence of vascular precursor cells[J]. PLoS One, 2018, 13(3):e0193749. DOI: 10.1371/journal.pone.0193749.
|
[45] |
ISHIKAWA Y, KASUYA T, ISHIKAWA J, et al. A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus[J]. Ther Clin Risk Manag, 2018, 14:1149-1153. DOI: 10.2147/TCRM.S167109.
|
[46] |
MARTÍN MC, CRISTIANO E, VILLANUEVA M, et al. Esophageal atresia and prenatal exposure to mycophenolate[J]. Reprod Toxicol, 2014, 50:117-121. DOI: 10.1016/j.reprotox.2014.10.015.
|
[47] |
HUANG CP, CHEN CC, TSAI YT, et al. Intravesical administration of xenogeneic porcine urothelial cells attenuates cyclophosphamide-induced cystitis in mice[J]. Cell Transplant, 2019, 28(3):296-305. DOI: 10.1177/0963689718822773.
|
[48] |
ŠTENGLOVÁ NETÍKOVÁ IR, PETRUŽELKA L, ŠŤASTNÝ M, et al. Safe decontamination of cytostatics from the nitrogen mustards family. part one: cyclophosphamide and ifosfamide[J] Int J Nanomedicine, 2018, 13:7971-7985. DOI: 10.2147/IJN.S159328.
|
[49] |
CLARK KL, KEATING AF. Ataxia-telangiectasia mutated coordinates the ovarian DNA repair and atresia-initiating response to phosphoramide mustard[J]. Biol Reprod, 2020, 102(1):248-260. DOI: 10.1093/biolre/ioz160.
|
[50] |
TECZA K, PAMULA-PILAT J, LANUSZEWSKA J, et al. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients[J]. Oncotarget, 2018, 9(10):9114-9136. DOI: 10.18632/oncotarget.24148.
|
[51] |
SUN X, ZHAO YN, QIAN S, et al. Ginseng-derived panaxadiol saponins promote hematopoiesis recovery in cyclophosphamide-induced myelosuppressive mice: potential novel treatment of chemotherapy-induced cytopenias[J]. Chin J Integr Med, 2018, 24(3):200-206. DOI: 10.1007/s11655-017-2754-8.
|
[52] |
MIELCAREK M, FURLONG T, O'DONNELL PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation[J]. Blood, 2016, 127(11):1502-1508. DOI: 10.1182/blood-2015-10-672071.
|
[53] |
FLOYD JD, NGUYEN DT, LOBINS RL, et al. Cardiotoxicity of cancer therapy[J]. J Clin Oncol, 2005, 23(30):7685-7696. DOI: 10.1200/JCO.2005.08.789.
|
[54] |
MARTEL RR, KLICIUS J, GALET S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic[J]. Can J Physiol Pharmacol, 1977, 55(1):48-51. DOI: 10.1139/y77-007.
|
[55] |
KLAWITTER J, NASHAN B, CHRISTIANS U. Everolimus and sirolimus in transplantation-related but different[J]. Expert Opin Drug Saf, 2015, 14(7):1055-1070. DOI: 10.1517/14740338.2015.1040388.
|
[56] |
WONG M. Mammalian target of rapamycin (mTOR) pathways in neurological diseases[J]. Biomed J, 2013, 36(2):40-50. DOI: 10.4103/2319-4170.110365.
|
[57] |
HOEGH-PETERSEN M, AMIN MA, LIU Y, et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graft-vs-host disease without increasing relapse[J]. Bone Marrow Transplant, 2013, 48(1):105-114. DOI: 10.1038/bmt.2012.99.
|
[58] |
COSIMI AB, COLVIN RB, BURTON RC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts[J]. N Engl J Med, 1981, 305(6):308-314. DOI: 10.1056/NEJM198108063050603.
|
[59] |
OTTO G, THIES J, KRAUS T, et al. Monoclonal anti-CD25 for acute rejection after liver transplantation[J]. Lancet, 1991, 338(8760):195. DOI: 10.1016/0140-6736(91)90192-r.
|
[60] |
WARD NC, YU A, MORO A, et al. IL-2/CD25: a long-acting fusion protein that promotes immune tolerance by selectively targeting the IL-2 receptor on regulatory T cells[J]. J Immunol, 2018, 201(9):2579-2592. DOI: 10.4049/jimmunol.1800907.
|
[61] |
BAAN CC, KANNEGIETER NM, FELIPE CR, et al. Targeting JAK/STAT signaling to prevent rejection after kidney transplantation: a reappraisal[J]. Transplantation, 2016, 100(9):1833-1839. DOI: 10.1097/TP.0000000000001226.
|
[62] |
PÉREZ-JELDRES T, TYLER CJ, BOYER JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists[J]. Front Pharmacol, 2019, 10:212. DOI: 10.3389/fphar.2019.00212.
|
[63] |
ANIL KUMAR MS, PAPP K, TAINAKA R, et al. Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate-to-severe plaque psoriasis[J]. Biopharm Drug Dispos, 2018, 39(5):245-255. DOI: 10.1002/bdd.2130.
|
[64] |
GOLDWATER R, KEIRNS J, BLAHUNKA P, et al. A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects[J]. Am J Transplant, 2013, 13(4):1040-1046. DOI: 10.1111/ajt.12082.
|
[65] |
VINCENTI F, KLINTMALM G, YANG H, et al. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation[J]. Am J Transplant, 2020, 20(1):172-180. DOI: 10.1111/ajt.15560.
|
[66] |
O'CONNELL PJ, KUYPERS DR, MANNON RB, et al. Clinical trials for immunosuppression in transplantation: the case for reform and change in direction[J]. Transplantation, 2017, 101(7):1527-1534. DOI: 10.1097/TP.0000000000001648.
|
[67] |
LIU Q, SMITH AR, PARK JM, et al. The adoption of generic immunosuppressant medications in kidney, liver, and heart transplantation among recipients in Colorado or nationally with medicare part D[J]. Am J Transplant, 2018, 18(7):1764-1773. DOI: 10.1111/ajt.14722.
|
[68] |
ROUSSEAU B, GUILLEMIN A, DUVOUX C, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma[J]. Int J Cancer, 2019, 144(4):886-896. DOI: 10.1002/ijc.31769.
|
[69] |
BENKHOUCHA M, MOLNARFI N, KAYA G, et al. Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes[J].EMBO Rep, 2017, 18(9):1545-1558. DOI:10.15252/embr. 201744075.
|